

ROS1 protein inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/R69388E13C40EN.html>

Date: January 2022

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: R69388E13C40EN

Abstracts

This report can be delivered to the clients within 3-4 Business Days

DelveInsight's, "ROS1 protein inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in ROS1 protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

ROS1 protein inhibitors Understanding

ROS1 protein inhibitors: Overview

ROS1 is a pivotal transmembrane receptor protein tyrosine kinase which regulates several cellular processes like apoptosis, survival, differentiation, proliferation, cell migration, and transformation. There is increasing evidence supporting that ROS1 plays an important role in different malignancies including glioblastoma, colorectal cancer, gastric adenocarcinoma, inflammatory myofibroblastic tumor, ovarian cancer, angiosarcoma, and non small cell lung cancer; thus, ROS1 has become a potential drug discovery target. ROS1 shares about 49% sequence homology with ALK primary structure; therefore, wide range of ALK kinase inhibitors have shown in vitro inhibitory activity against ROS1 kinase.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence ROS1 protein inhibitors R&D. The therapies under development are focused on novel approaches for ROS1 protein inhibitors.

ROS1 protein inhibitors Emerging Drugs Chapters

This segment of the ROS1 protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

ROS1 protein inhibitors Emerging Drugs

Alkotinib: Suzhou Zelgen Biopharmaceuticals

Alkotinib Capsules are being tested in two Phase II clinical trials for the efficacy and safety of ALK-positive patients with advanced NSCLC for whom the Crizotinib therapy fails and for ALK-positive, non-small cell lung cancer patients with brain metastases.

APG-2449: Ascentage Pharma

APG-2449 is a potent, orally bioavailable inhibitor of the focal adhesion kinase, or FAK, ROS1 and anaplastic lymphoma kinase, or ALK, kinases, which we are developing for the treatment of cancer. APG-2449 has demonstrated antitumor activity in multiple xenograft tumor models. Studies in preclinical tumor models have shown that APG-2449 overcomes the drug resistance to the first generation ALK inhibitors, and exhibits synergistic effects with EGFR inhibitors (especially the newly approved third generation AZD9291/osimertinib) in an EGFR T790M mutant NSCLC xenograft tumor model.

Further product details are provided in the report.....

ROS1 protein inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different ROS1 protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on ROS1 protein inhibitors

There are approx. 10+ key companies which are developing the ROS1 protein inhibitors. The companies which have their ROS1 protein inhibitors drug candidates in the most advanced stage, i.e. Phase II include Suzhou Zelgen Biopharmaceuticals.

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

ROS1 protein inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

ROS1 protein inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I,

preclinical and discovery stage. It also analyses ROS1 protein inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging ROS1 protein inhibitors drugs.

ROS1 protein inhibitors Report Insights

ROS1 protein inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

ROS1 protein inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing ROS1 protein inhibitors drugs?

How many ROS1 protein inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of ROS1 protein inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the ROS1 protein inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for ROS1 protein inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Suzhou Zelgen Biopharmaceuticals

Ascentage Pharma

Xuanzhu Biopharmaceutical

Pfizer

Turning Point Therapeutics

Roche

Fochon Pharma

Eli Lilly and Company

Daiichi Sankyo Inc

Chia Tai Tianqing Pharmaceutical Group

Xcovery

Key Products

Alkotinib

APG-2449

XZP 3621

Lorlatinib

Crizotinib

Repotrectinib

Entrectinib

TQ B3101

Foritinib succinate

Taletrectinib

Merestinib

Ensartinib

Contents

Introduction

Executive Summary

ROS1 protein inhibitors: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

ROS1 protein inhibitors – DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

Comparative Analysis

Ensartinib: Xcovery

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Alkotinib: Suzhou Zelgen Biopharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

APG-2449: Ascentage Pharma

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

ROS1 protein inhibitors Key Companies

ROS1 protein inhibitors Key Products

ROS1 protein inhibitors- Unmet Needs

ROS1 protein inhibitors- Market Drivers and Barriers

ROS1 protein inhibitors- Future Perspectives and Conclusion

ROS1 protein inhibitors Analyst Views

ROS1 protein inhibitors Key Companies

Appendix

I would like to order

Product name: ROS1 protein inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/R69388E13C40EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R69388E13C40EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970